Literature DB >> 11137612

Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro.

C A Baumann1, M Badamchian, A L Goldstein.   

Abstract

It is well established that glucocorticoid hormones induce apoptosis in immature developing thymocytes. Thymocyte apoptosis can be modulated by growth factors, anti-oxidants and adhesion receptors. We have previously demonstrated that thymosin alpha1 (Talpha1) antagonizes dexamethasone-induced apoptosis of CD4+CD8+ thymocytes. In the present study, we further characterize the dose and time dependence of Talpha1's antagonism of dexamethasone-induced thymocyte apoptosis. Talpha1 is effective at concentrations ranging from 2 to 100 microg/10(6) thymocytes. Talpha1 pre-treatment is necessary to achieve its anti-apoptotic activity. Talpha1 provides temporary protection to thymocytes by slowing dexamethasone's apoptotic activity up to 12 h post dexamethasone treatment. Additionally, Talpha1's activity is not sensitive to cycloheximide treatment, suggesting Talpha1's activity is independent of protein synthesis. Finally, Talpha1 is unable to antagonize apoptosis induced by the reactive oxygen species, H2O2, suggesting Talpha1's antagonism of dexamethasone occurs at the early stages of dexamethasone-induced apoptosis, prior to the production of reactive oxygen species. This evidence suggests that Talpha1 may provide a mechanism to transiently extend the life of a thymocyte during thymic selection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137612     DOI: 10.1016/s0192-0561(00)00065-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

1.  A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy.

Authors:  D Chadwick; J Pido-Lopez; A Pires; N Imami; F Gotch; J S Villacian; S Ravindran; N I Paton
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

2.  The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model.

Authors:  Haiping He; Yulin Cen; Ping Wang; Xu Zeng; Shan Zeng; Xinlong Li; Xiaofei Lu; Chuanhong Zhong; Yang Ming; Ligang Chen; Lilei Peng
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-06       Impact factor: 4.322

3.  Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function.

Authors:  Lanzhou Li; Chenfei Zhao; Fange Kong; Yi-Cong Li; Chunxia Wang; Shanshan Chen; Hor-Yue Tan; Yang Liu; Di Wang
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

4.  The use of growth factors to modulate the activities of antigen-specific CD8+ T cells in vitro.

Authors:  F Q Alenzi; F A Alenazi; Y Al-Kaabi; M L Salem
Journal:  J Med Life       Date:  2011-11-24

5.  Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life.

Authors:  Fanwen Wang; Tingting Yu; Heng Zheng; Xingzhen Lao
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

6.  Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo.

Authors:  Renhao Peng; Caoying Xu; Heng Zheng; Xingzhen Lao
Journal:  ACS Omega       Date:  2020-04-27

Review 7.  The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy.

Authors:  Hong-Yuan Lin
Journal:  Chin J Traumatol       Date:  2020-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.